Sitagliptin (Situviamet)
Sitagliptin
Cipla Medpro (Pty) Ltd
Registration
- Applicant
- Cipla Medpro (Pty) Ltd
- Registrations
- 2
- Schedule source
- Consolidated Schedules 06 July 2026
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Situviamet 50 mg/500 MG EACH TABLET CONTAINS METFORMIN HYDROCHLORIDE 500,0 mg; SITAGLIPTIN PHOSPHATE EQUIVALENT TO SITAGLIPTIN 50,0 mg | 50 mg/500 mg | 54049754/21.2/0497 | Registered | S3 | None |
| Situviamet 50 mg/1 000 MG ECAH TABLET CONTAINS METFORMIN HYDROCHLORIDE 1 000,0 mg SITAGLIPTIN PHOSPHATE EQUIVALENT TO SITAGLIPTIN 50,0 mg | 50 mg 000 mg /1 | 54049854/21.2/0498 | Registered | S3 | None |
Regulatory status
Where S3 sits on the scale
Needs a doctor's prescription, dispensed by a pharmacist.
Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S3, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Metformin hydrochloride, sitagliptin phosphate equivalent to sitagliptin
S3: Sitagliptin phosphate
Consolidated Schedules 06 July 2026, line 4249
Pharmacological class: Oral hypoglycaemics. (class 21.2)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(3R)-3-Amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
Drag to rotate. Structure from PubChem CID 4369359.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.